Low‐FODMAP diet for pediatric patients with disorders of gut‐brain interaction: A systematic review and meta‐analysis
Journal of Parenteral and Enteral Nutrition · 17.08.2026
DOI: 10.1002/jpen.70135 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Parenteral and Enteral Nutrition, online erschienen am 17.08.2026. Verfasst von Pedro Henrique Silva de Oliveira Souza und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Federal University of Sergipe, Lagarto, Sergipe, Brazil. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: None.
Abstract (Originalsprache)
Objectives
The role of a low‐FODMAP diet in pediatric disorders of gut–brain interaction (DGBIs), particularly irritable bowel syndrome (IBS) and functional abdominal pain (FAP), is unclear. This review synthesized evidence on its efficacy in children and adolescents with IBS or FAP.
Methods
PubMed, Embase, CENTRAL, and Web of Science were searched through May 2025 following PRISMA guidelines. Randomized and observational studies evaluating a low‐FODMAP diet were included. The primary outcome was abdominal pain intensity, evaluated using both continuous and dichotomous measures. Secondary outcomes included pain frequency (also assessed using continuous and dichotomous measures), stool frequency, and patient satisfaction. Random‐effects single‐arm meta‐analyses with subgroup analyses by diagnosis (IBS vs. FAP) were conducted.
Results
Ten studies ( N = 612) were included: eight evaluated IBS and six FAP. The diet significantly reduced abdominal pain intensity (SMD –1.37; 95% CI –2.18 to –0.57), with larger effects in IBS. Pain frequency improved in IBS (SMD –1.23; 95% CI –2.01 to –0.45) but not in FAP. Stool frequency showed no significant effect (SMD –0.26; 95% CI –0.97 to 0.45). Overall satisfaction was higher in IBS (83%) than in FAP (43%). Heterogeneity was substantial, and risk of bias was frequent, especially in observational studies.
Conclusions
A low‐FODMAP diet may improve abdominal pain and satisfaction in pediatric IBS, while benefits for FAP are less certain. High heterogeneity and methodological limitations highlight the need for further controlled trials to confirm efficacy, evaluate long‐term safety, and guide clinical recommendations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Federal University of Sergipe, Lagarto, Sergipe, Brazil.
- Systematic Reviews Center for Cardiovascular and Metabolic Health, São Paulo State University, School of Philosophy and Sciences, Marília, São Paulo, Brazil.
- Department of Health Education, Federal University of Sergipe, Lagarto, Sergipe, Brazil.
- Department of Pediatrics, Hospital Albert Einstein, São Paulo, São Paulo, Brazil.
- Faculty of Medicine, University of São Paulo, FMUSP, São Paulo, São Paulo, Brazil.
ORCID-Profile: Pedro Henrique Silva de Oliveira Souza
Förderung
- None
Zitieren
APA
Souza, P. H. S. O., Coêlho, J. R. C., de Andrade, A. M., Marques, K. S., Valenti, V. E., Menezes, F. D. S., & Sandy, N. S. (2026). Low‐FODMAP diet for pediatric patients with disorders of gut‐brain interaction: A systematic review and meta‐analysis. Journal of Parenteral and Enteral Nutrition. https://doi.org/10.1002/jpen.70135
Vancouver
Souza PHSO, Coêlho JRC, de Andrade AM, Marques KS, Valenti VE, Menezes FDS, et al. Low‐FODMAP diet for pediatric patients with disorders of gut‐brain interaction: A systematic review and meta‐analysis. Journal of Parenteral and Enteral Nutrition. 2026. doi:10.1002/jpen.70135
BibTeX
@article{Souza2026,
author = {Souza, Pedro Henrique Silva de Oliveira and Coêlho, João Ricardo Coutinho and de Andrade, Alexandre Machado and Marques, Kauã Santana and Valenti, Vitor Engrácia and Menezes, Fabrício Dos Santos and Sandy, Natascha Silva},
title = {Low‐FODMAP diet for pediatric patients with disorders of gut‐brain interaction: A systematic review and meta‐analysis},
journal = {Journal of Parenteral and Enteral Nutrition},
year = {2026},
doi = {10.1002/jpen.70135}
}
EUVIMED